

TECHNICAL DATA SHEET

# Purified Anti-Mouse CD86 (B7-2) (PO3.1)

Catalog Number: 70-0861

## PRODUCT INFORMATION

**Contents:** Purified Anti-Mouse CD86 (B7-2) (PO3.1)

**Isotype:** Rat IgG2b, kappa

**Concentration:** 0.5 mg/mL

**Clone:** PO3.1

**Reactivity:** Mouse

**Formulation:** 10 mM NaH<sub>2</sub>PO<sub>4</sub>, 150 mM NaCl, 0.09% NaN<sub>3</sub>, pH7.2

## DESCRIPTION

The PO3.1 antibody reacts with mouse CD86, also known as B7-2, an 80 kDa cell surface protein which is a ligand for CD28, a co-stimulatory receptor for the T cell receptor (TCR). CD28 can also bind a second B7 ligand known as CD80 (B7-1). Both CD80 and CD86 are expressed on activated B cells and antigen-presenting cells. These ligands trigger CD28 signaling in concert with TCR activation to drive T cell proliferation, induce high-level expression of IL-2, impart resistance to apoptosis, and enhance T cell cytotoxicity. The interaction / co-stimulatory signaling between the B7 ligands and CD28 provides crucial communication between T cells and B cells or APCs to coordinate the adaptive immune response. The PO3.1 antibody may be used as a marker for CD86 expression on B cells, macrophages, and dendritic cells.

## PREPARATION & STORAGE

This monoclonal antibody preparation was purified from tissue culture supernatant via affinity chromatography. For In Vivo Ready™ (IVR) products, each preparation is also evaluated for endotoxin levels using the LAL assay. It is recommended to store the product undiluted at 4°C. Do not freeze.

## APPLICATION NOTES

This purified format is guaranteed to be >90% pure as determined by SDS-PAGE analysis. Citations are provided as a convenience to you - please consult Materials and Methods sections for additional details about the use of any product in these publications.

## REFERENCES

Ioannou M, Alissafii T, Lazaridis I, Deraos G, Matsoukas J, Gravanis A, Mastorodemos V, Plaitakis A, Sharpe A, Boumpas D, and Vergiinis P. 2012. J. Immunol. 188: 1136-1146. (flow cytometry) Zhang J, Kawashima N, Suda H, Nakano Y, Takano Y, and Azuma M. 2006. Int. Immunol. 18: 1375-1384. (immunohistochemistry – frozen tissue) Kin NW and Sanders VM. 2006. J. Immunol. 176: 6727 – 6735. (in vitro activation) Spadaro M, Ambrosino E, Iezzi M, Di Carlo E, Sacchetti P, Curcio C, Amici A, Wei W-Z, Musiani P, Lollini P-L, Cavallo F, Forni G. 2005. Clin. Cancer Res. 11: 1941-1952. (immunohistochemistry – frozen tissue) Pokojil JR, Kin NW, and Sanders VM. 2004. 279: 23394-23404. (in vitro activation) Iwai H, Kozono Y, Hirose S, Akiba H, Yagita H, Okumura K, Kohsaka H, Miyasaka N, and Azuma M. 2002. J. Immunol. 169: 4332-4339. (in vitro activation)

NOTE: Please choose the appropriate format for each application. Citations are provided as a convenience to you; please consult Materials and Methods sections for additional details about the use of any product in these publications.

## For Research Use Only.

Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Tonbo Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Tonbo Biosciences, Tonbo Biosciences Logo and all other trademarks are the property of Tonbo Biotechnologies Corporation. © 2013 Tonbo Biosciences.